ATOH8通过抑制SCD表达来赋予瘤细胞对铁亡的脆弱性
Huixiang Xiao1, Xinxing Du2, Huan Hou3
1State Key Laboratory of Systems Medicine for Cancer, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
转录因子ATOH8通过抑制醇-甲酸脱酶 (SCD) 来调节铁亡. EZH2在表观遗传上控制ATOH8,并与铁灭诱导剂一起抑制EZH2显示了癌症的治疗潜力.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 转录调节对于细胞铁亡至关重要,但机制尚不清楚.
- 铁亡是一种依赖于铁的细胞死亡途径,在癌症中具有治疗意义.
研究的目的:
- 确定涉及铁灭调节的关键转录因子.
- 阐明将转录和表观遗传调节与铁亡联系起来的分子机制.
- 探索向癌症中已识别的途径的治疗潜力.
主要方法:
- 通过基因表达分析确定ATOH8作为铁灭调节剂.
- 功能性研究涉及ATOH8过度表达和瘤细胞的删除.
- 关于ATOH8在调节醇-甲酸脱酶 (SCD) 转录中的作用的机制研究.
- 通过EZH2对ATOH8表达的上游表观遗传调节的分析.
- 在体外和体内实验评估联合EZH2抑制和ferroptosis诱导的实验.
主要成果:
- ATOH8通过铁灭菌诱导剂进行上调,并促进铁灭菌敏感性.
- ATOH8抑制了SCD转录,增加了ferroptosis的易感性.
- TCF3与ATOH8一起作为辅助因子,抑制SCD转录.
- EZH2通过DNA甲基化和H3K27me3.3通过表观遗传抑制ATOH8的表达.
- 联合EZH2抑制和ferroptosis诱导显著抑制瘤生长.
结论:
- ATOH8是ferroptosis敏感性的一个关键调节器.
- 该TCF3-ATOH8复合体抑制SCD,调节铁亡.
- 通过EZH2介导的ATOH8表观遗传沉默是 Ferroptosis逃避的一个关键机制.
- 向EZH2和铁亡途径为癌症治疗提供了一个有前途的治疗策略.
更多相关视频
09:21Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
Published on: February 23, 2024
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
Published on: September 26, 2019
相关概念视频
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
